OTC · VIRX
Healthcare · Biotechnology
$0.01
Up+$0.00 (+0.00%)
Updated Aug 24, 2026, 1:56 AM
SID Score
3.8/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 0 trading sessions · Daily adjusted prices
VIRX does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning VIRX.
VIRX research
Company profile and research snapshot.
Viracta Therapeutics, Inc., a precision oncology company, engages in developing drugs for the treatment of virus-associated malignancies. Its lead product candidature includes Nana-val, in combination with nanatinostat and valganciclovir that is in Phase II clinical trial for Epstein-Barr virus-positive lymphoma; and open-label Phase 2 basket trial for the treatment of various relapsed/refractory Epstein-Barr virus-positive (EBV+) lymphoma, as well as an open-label Phase 1b/2 trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The company's development pipeline includes vecabrutinib, a clinical-stage non-covalent ITK/BTK inhibitor and VRx-510 (formerly SNS-510), a preclinical-stage PDK-1 inhibitor. It is evaluating development and collaboration opportunities for vecabrutinib in combination with chimeric antigen receptor T-cell therapies and VRx-510 in various oncology indications. The company was formerly known as Sunesis Pharmaceuticals, Inc. to Viracta Therapeutics, Inc. in February 25, 2021. Viracta Therapeutics, Inc. was incorporated in 1998 and is headquartered in Cardiff-by-the-Sea, California.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 27, 2024 | Rodman & Renshaw | Neutral | — |
| Nov 14, 2024 | RBC Capital | Outperform | — |
| Aug 16, 2024 | Leerink Partners | Market Perform | — |
| Aug 15, 2024 | RBC Capital | Outperform | — |
| May 23, 2024 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
GlobeNewswire Inc. · Feb 5, 2025
Viracta Therapeutics, a clinical-stage precision oncology company, has announced the termination of its employees and the wind-down of its operations. The company is exploring potential strategic alternatives for its development programs.
Benzinga · Dec 27, 2024
Party City filed for Chapter 11 bankruptcy for the second time in two years, unable to overcome challenges like inflation and poor leadership. Big Lots failed to find a buyer, while The Container Store is restructuring its finances to emerge as a private company. Viracta Therapeutics is considering a sale, and TPG is in talks to acquire Altus Power, a solar energy provider.
GlobeNewswire Inc. · Dec 26, 2024
Viracta Therapeutics has decided to close its ongoing NAVAL-1 clinical trial for the treatment of relapsed/refractory EBV+ lymphomas while the company explores strategic alternatives, including a potential merger, licensing agreement, or sale.
GlobeNewswire Inc. · May 17, 2024
SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that, in connection with the appointment of Michael Faerm as Viracta’s new Chief Financial Officer, Viracta’s Board of Directors granted Mr. Faerm a non-qualified stock option to purchase 500,000 shares of common stock under Viracta’s 2021 Inducement Equity Incentive Plan. Additionally, Viracta's Board of Directors approved the grant of non-qualified stock options to a new non-executive employee to purchase 10,000 shares of common stock. Each option vests over four years, with 25% of the shares subject to each option vesting on May 13, 2025, and the remaining 75% of the shares subject to each option vesting in equal monthly increments over the succeeding 36 months, in each case subject to the respective grantee’s continuous service to Viracta through each vesting date. Each option has an exercise price of $0.804 per share, which is equal to the closing price per share of Viracta’s common stock on May 14, 2024, the grant date of each option.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning VIRX.
No results
No recent SID articles mention VIRX.
